Cohbar (OTCMKTS:CWBR) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday, December 1st.
Cohbar (CWBR) opened at $5.50 on Friday. Cohbar has a 1-year low of $1.60 and a 1-year high of $7.60.
TRADEMARK VIOLATION WARNING: This report was first posted by Week Herald and is the property of of Week Herald. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://weekherald.com/2017/12/13/cohbar-cwbr-cut-to-sell-at-valuengine.html.
CohBar, Inc, a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cohbar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cohbar and related companies with MarketBeat.com's FREE daily email newsletter.